- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02554552
Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee
A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YY1201 Once in the Treatment of Patients With Osteoarthritis of the Knee
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Seoul, Korea, Republikken
- Samsung Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Males or Females 40 years and older
According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings.
- Over 50 years of age
- Less than 30 minutes of morning stiffness
- Crepitus on active motion
- 4 bony tenderness
- Bony enlargement
- Nopalpable warmth of synvium
- Within 6 months from screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination.
- By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the single or both sides of the osteoarthritis is over 40mm
- Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past.
- Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.)
- Patient who agrees to participate in this clinical trial by themselves.
Exclusion Criteria:
- Someone who has BMI≥32kg/m² at the screening visit.
- Patient who has an experience dosing psychoactive drug, narcotic analgesic which can have an effect on pain sense over 3 months habitually.
- Patient who has been administrated gastrointestinal drug(for example H₂-blockers, misoprostol or proton pump inhibitors) regularly, who can't stop injecting for clinical study period.
- Patient has attended abnormal values from screening test(2 times excess at upper limit of the normal values at ALT, AST, BUN, Serum Creatinine).
- Patient who has rheumarthritis or other inflammatory metabolic arthritis.
- Patients having serious gastrointestinal, liver, renal, heart disease.
- When the inflammatory disease is occurred on joint area to patient like septic arthritis.
- Patients having skin ailment at the injecting site of the joint region.
- Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis or systemic disease.
- Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc herniation.
- Poly-articular patients who have suffered seriously by osteoarthritis at other parts affect judge of the knee joint pain.
- Patients who diagnosed clear interval disappearance at the knee joint by X-ray.
Patients who were administrated below drugs before baseline visit.
- Patients who were injected HA at the target knee joint in recent 9 months.
- Patients who were injected HA at other parts of the knee joint in recent 6 months.
- Patients who were injected steroids into the intra-articular knee joint.
- Patients who were administrated steroids systemically by the oral medication (But, except inhalation)
- Patients who have joint effusion trouble were judged as a positive by tests like Patella tap test.
- Patients who have target knee joint gotten surgical operation history including Arthroscopy within past one year (In case of having other side of knee joint or hip joint gotten surgical operation history, excepting the patients if there is possibility which can influence the target knee joint's appraisal.
- Patients who have an operation history about target knee joint.
- Patients who do the height weight aerobic exercise or anaerobic exercise.
- Patients who need to be administrated anticoagulant agent together(But, except 300mg daily dose aspirin)
- Patients who have hypersensitivity history about Investigational Product.
In the midst of women in their childbearing years, patients who disagree to do * contraception by medically permitted method for 12 weeks from administrating investigational product.
* The contraception by medically permitted method: Condom, In case of using injection or insertion, In case of installing a intrauterine contraception device etc.
- Patients who were injected other investigational product over a time within 30 days before participated in this clinical trail.
- Besides that, the patients who have difficulty to be participated in this clinical trial continuously by Principle Investigator (PI)'s decision.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: YY1201 2ml
|
YY1201 2ml
|
Eksperimentell: YY1201 3ml
|
YY1201 2ml
|
Placebo komparator: Placebo 2ml
Phosphate buffered saline 2ml
|
phosphate buffered saline 2ml
Andre navn:
|
Placebo komparator: Placebo 3 ml
Fosfatbufret saltvann 3ml
|
fosfatbufret saltvann 3ml
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Variation of the Weight-bearing pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline
Tidsramme: Week 4 and Week 12
|
Week 4 and Week 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Variation of the KOOS scales on the 4, 12 weeks after administration in comparison with baseline
Tidsramme: Week 4 and Week 12
|
Week 4 and Week 12
|
Variation of the rest pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline
Tidsramme: Week 4 and Week 12
|
Week 4 and Week 12
|
Bevegelsessmerter (100 mm-VAS) på 4, 12 uker etter administrering sammenlignet med baseline
Tidsramme: Uke 4 og uke 12
|
Uke 4 og uke 12
|
Pasientens globale vurdering (100 mm-VAS) 4, 12 uker etter administrering med baseline
Tidsramme: Uke 4 og uke 12
|
Uke 4 og uke 12
|
Undersøkers global vurdering (100 mm-VAS) 4, 12 uker etter administrering
Tidsramme: Uke 4 og uke 12
|
Uke 4 og uke 12
|
Endring av hevelsen i kneleddet fra baseline til 4, 12 uker etter administrering
Tidsramme: Uke 4 og uke 12
|
Uke 4 og uke 12
|
Endring av ømhet ved trykk i kneleddet fra baseline til 4, 12 uker etter administrering
Tidsramme: Uke 4 og uke 12
|
Uke 4 og uke 12
|
Rate of change of the Range Of Motion(ROM) in the knee joint on 4, 12 weeks after administration with baseline
Tidsramme: Week 4 and Week 12
|
Week 4 and Week 12
|
Bruk av redningsmedisiner teller og totalmengde på 4, 12 uker
Tidsramme: Uke 4 og uke 12
|
Uke 4 og uke 12
|
Responsrate for vektbærende smerte på 12 uker sammenlignet med baseline
Tidsramme: Uke 12
|
Uke 12
|
Responsrate for OMERACT-OARSI på 12 uker sammenlignet med baseline
Tidsramme: Uke 12
|
Uke 12
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Chul-Won Ha, M.D., Samsung Medical Center, Department of Internal Medicine
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- YY_YY1201_001/2a
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Artrose, kne
-
Smith & Nephew, Inc.Nor Consult, LLCFullførtJourney II XR Total Knee SystemForente stater
-
Smith & Nephew, Inc.FullførtJourney II BCS Total Knee SystemForente stater, Belgia, New Zealand
-
Smith & Nephew, Inc.Nor ConsultFullførtJourney II CR Total Knee SystemForente stater
-
Central DuPage HospitalAvsluttetTotalt kneskifte | Erstatning, Total Knee | Artroplastikk, kneproteseForente stater
-
University of VirginiaFullførtArtrose | Tibial Femoral Knee ArtroseForente stater
-
Bispebjerg HospitalFullførtPatellar Tendinopathy / Jumpers KneeDanmark
-
Istituto Ortopedico RizzoliRekrutteringOsteochondritis Dissecans KneeItalia
-
3D Metal Printing LtdUniversity of BathUkjentUnicompartmental Medial Knee ArtroseItalia
-
Maxx Orthopedics IncRekrutteringBein tap | Periprotetiske brudd | Infeksjon | Aseptisk løsning | MCL - Medial Collateral Ligament Rupture of the KneeForente stater
-
Boston Children's HospitalTexas Scottish Rite Hospital for ChildrenRekrutteringPsykologisk stress | Osteochondritis Dissecans KneeForente stater
Kliniske studier på YY1201 2ml
-
Ahmad Jabir RahyussalimUkjentSmerte i korsryggen | Degenerativ skivesykdom | DiskdegenerasjonIndonesia
-
National Taiwan University HospitalFullført
-
Yooyoung Pharmaceutical Co., Ltd.FullførtArtrose, kneKorea, Republikken
-
Medipost Co Ltd.FullførtAlzheimers sykdomKorea, Republikken
-
Medipost Co Ltd.FullførtAlzheimers sykdomKorea, Republikken
-
Centre Hospitalier du Centre du ValaisUkjentTrombose | Feilfunksjon; Kateter | Mekanisk komplikasjon av hemodialysekateterSveits
-
Yooyoung Pharmaceutical Co., Ltd.Fullført
-
Hospital Civil de GuadalajaraRekrutteringAnestesi | Obstetriske anestesiproblemerMexico
-
Novartis PharmaceuticalsHar ikke rekruttert ennåLeddgikt | Systemisk lupus erythematosus | Sjögrens sykdom
-
WinSanTor, IncFullførtPerifer nevropati | Smertefull diabetisk nevropati | Diabetiske nevropatier, smertefullCanada